MRNA cancer shots: new hope or hype?

NCT ID NCT06880549

Recruiting now Disease control Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab. The main goal is to check safety and find the right dose, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA-4106 and mRNA-4200 (mRNA-based therapies) with or without pembrolizumab (immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 42 people, so it is primarily checking safety and dosing. The treatments may not shrink tumors or work for everyone, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma carcinoma of esophagus cervical cancer cervical carcinoma colorectal adenocarcinoma endometrial carcinoma gastric cancer gastric carcinoma head and neck squamous cell carcinoma hepatocellular carcinoma melanoma neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer ovarian carcinoma Recurrence urinary bladder cancer urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

START Los Angeles
NOT_YET_RECRUITING

Los Angeles, California, 90025, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.